Psilocybin Tied to Fewer Symptoms With Major Depressive Disorder
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 5, 2023 -- Psilocybin treatment is associated with a clinically significant sustained reduction in depressive symptoms and functional disability in individuals with major depressive disorder (MDD), according to a phase 2 study published online Aug. 31 in the Journal of the American Medical Association.
Charles L. Raison, M.D., from Usona Institute in Fitchburg, Wisconsin, and colleagues evaluated the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. The analysis included 104 adults (aged 21 to 65 years) with MDD who were randomly assigned (1:1) to receive a single dose of psilocybin or niacin placebo.
The researchers found that psilocybin treatment was associated with significantly reduced Montgomery-Asberg Depression Rating Scale scores versus niacin from baseline to day 43 (mean difference, −12.3; P < 0.001) and from baseline to day 8 (mean difference, −12.0; P < 0.001). There was also a significant reduction in Sheehan Disability Scale scores for psilocybin treatment compared with niacin (mean difference, −2.31; P < 0.001) from baseline to day 43. Compared with niacin treatment, more participants receiving psilocybin had sustained response (but not remission). Psilocybin treatment was associated with a higher rate of overall adverse events (AEs) and a higher rate of severe AEs, but there were no serious treatment-emergent AEs.
“These findings add to increasing evidence that psilocybin -- when administered with psychological support -- may hold promise as a novel intervention for MDD,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Risk of Suicide, Homicide Both Higher at Night
FRIDAY, June 7, 2024 -- The risk of suicide and homicide is higher at night than might be expected based on the number of people awake at that time, according to a study published...
Social Media Use Tied to Depression, but Not Sole Cause in Young Adults
FRIDAY, June 7, 2024 -- Social media use and depression are associated, but social media use is not prospectively related to the course of depressive symptoms, according to a...
Many Patients Have Discontinuation Symptoms After Stopping Antidepressants
THURSDAY, June 6, 2024 -- A considerable proportion of patients have discontinuation symptoms (e.g., dizziness, headache, nausea, insomnia, and irritability) after...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.